News

Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia

Shionogi Announces Corporate Reorganization and Personnel Reassignment

Shionogi Healthcare, Shionogi, and Pixie Dust Technologies Enter a Business Partnership Agreement to Launch Business Involving Brain Activation through Sound Stimulation
- Aiming to Start Selling Products to Ordinary Households in Spring 2023 -

Execution of Sub-license Agreement from Ping An-Shionogi Hong Kong to Ildong for Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, for South Korea

Notice regarding the Beginning of Solar Power Generation at a Health Facility in Kilifi County, Kenya under the “Mother to Mother SHIONOGI Project”

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi Continuously Selected for Inclusion in All ESG Indices Adopted by the Government Pension Investment Fund (GPIF)

Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Shionogi & Co., Ltd. and Grünenthal GmbH Enter a License Agreement to Commercialize Injectable Resiniferatoxin for Osteoarthritis in Japan

Transcript of FY2022 Q1 Financial Results

Financial Results and supplement for FY2022 1Q

Presentation Materials for FY2022 1Q financial results

Execution of Sublicense Agreement with JEIL for New Siderophore Cephalosporin Antibacterial Drug Cefiderocol in South Korea

Notice Regarding the Initiation of a Fourth Vaccination Trial in subjects aged 60 and over for the COVID-19 Recombinant Protein-based Vaccine, S-268019

Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Initiation of a Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-based Vaccine, S-268019

S-217622, a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.4 And BA.5

Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)

Notice Regarding the Initiation of the Submission of Preparation Materials for a New Drug Application for S-217622, a Therapeutic Drug for COVID-19, in China

Notice Regarding the Launch of the new SHIONOGI Group Brand

Notice Regarding the Inclusion of Universal Antigen Vaccine Research into the Vaccine / New Modality Research and Development Project following a Public Solicitation by SCARDA

Shionogi Selected as a Member of the “SOMPO Sustainability Index” for the 11th Consecutive Year

Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan

Notice Regarding Acquisition and Cancellation of Treasury Stock (Acquisition of treasury stock pursuant to the provisions of Article 165, paragraph 2 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act)

Notice Regarding Disposition of Treasury Stock by way of Third-party Allotment

Conclusion of a basic agreement between Pixie Dust Technologies and Shionogi for joint research for improvement of cognitive function and brain activation by sound stimulation
~ With the vision of offering continual care for dementia patient in everyday life~

Presentation Material for Goldman Sachs Japan Thought Leaders Forum 2022

SHIONOGI SIGNS AGREEMENT WITH NHS ENGLAND TO BEGIN AN INNOVATIVE SUBSCRIPTION PAYMENT MODEL FOR REIMBURSEMENT OF ITS ANTIBIOTIC, FETCROJA® (CEFIDEROCOL)

Presentation Material for Press conference on the conclusion of landmark license and collaboration agreement by GARDP, CHAI and Shionogi

Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries

“Notice of Convocation of the 157th Annual General Meeting of Shareholders” and “Items Disclosed on Internet Concerning Notice of Convocation of the 157th Annual General Meeting of Shareholders”

Shionogi Announces appointment of Corporate officers, Corporate Reorganization and Personnel Reassignment

Transcript of Fiscal 2021 Financial Results Conference Call

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Notice Regarding the Initiation of a Phase 2/3 clinical trial in Japanese adolescents for the COVID-19 Recombinant Protein-based Vaccine, S-268019

Presentation Material for Conference Call of FY2021

Notice Regarding Establishment of the “Shionogi Infectious Disease Research Promotion Foundation”, a General Incorporated Foundation, and Disposition, Acquisition and Cancellation of Treasury Stock

Financial Results, Supplement, and Press conference Material for FY2021

Position and Policy Regarding Reduction of the Investment Unit

Notice of Revisions to Earnings and Dividend Forecasts

New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

Shionogi Presents Japanese Phase 2/3 Clinical Trial Results of COVID-19 Recombinant Protein-based Vaccine at Conference

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

Notice Regarding the Media Coverage about S-217622, a Therapeutic Drug for COVID-19

Shionogi expresses its support for the recommendations of Task Force on Climate-related Financial Disclosures (TCFD) and its participation in the TCFD Consortium

Shionogi has been Selected for the ESG Investment Index “FTSE Blossom Japan Sector Relative Index” Adopted by GPIF

AMR Action Fund Launches Investments to Promote Innovation to Overcome AMR

Continuation of the Cooperation Agreement with Aichi Prefecture on Drug Abuse Prevention

Notice Regarding Completion of Reorganization of Subsidiary through Company Merger

SMBC Nikko Web IR for Retail Investors

Notice Regarding the Signing of a Basic Agreement with the Ministry of Health, Labor and Welfare for Domestic Supply of S-217622, a Therapeutic Drug for COVID-19

Regarding the Filing for Approval of Cefiderocol in Japan

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S-217622

Shionogi Announces the Results of Comprehensive Maternal and Child Health Support Activities undertaken in Kenya under the “Mother to Mother SHIONOGI Project” —Health of Maasai Mothers and Children has Improved—

Shionogi provides humanitarian aid to Ukraine

Shionogi Presents the Interim Report (Top-line Results) of a Phase 2/3 Additional Dose Clinical Trial for the COVID-19 Vaccine, S-268019

Presentation Material for Briefing session on Phase 2/3 booster trial of COVID-19 vaccine "S-268019"

Shionogi Received a “Special Award” in the Category of Corporate Environmental Sustainability of the Ministry of the Environment’s 3rd ESG Finance Awards Japan

Shionogi and Ube Industries Enter into a Strategic Development Collaboration for the Novel Anti-RS Virus Drug Candidate S-337395

Conclusion of a Business Cooperation Agreement regarding Support for Children’s Bright Future with the City of Yokohama

Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan

SHIONOGI Announces Sponsorship of the Thematic Projects "Signature Pavilion" of Expo 2025 Osaka, Kansai, Japan

Shionogi has been recognized as one of the highest-ranking companies on the “Supplier Engagement Reporting Leaderboard (Climate Change)” by CDP

Shionogi has been Selected as one of the "Excellent Integrated Reports" by the GPIF's Domestic Equity Managers for the second consecutive year

Shionogi Announces the Conclusion of a Contract for the Establishment of a Research Department for Mucosal Vaccines with Chiba University Hospital.

Transcript of Briefing session on COVID-19 therapeutic drug "S-217622

SHIMADZU and SHIONOGI establishes joint venture AdvanSentinel —Helping society through better public health risk assessment, including wastewater surveillance—

Presentation Material for Briefing session on COVID-19 therapeutic drug "S-217622"

Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622

Transcript of 3rd Quarter of Fiscal 2021 Financial Results Conference Call

Shionogi Presents Clinical Trial Results of the COVID-19 Therapeutic Drug S-217622

Presentation Material for FY2021 Third Quarter Financial Results

Financial Results for the Third Quarter of FY2021

Notice Regarding the Progress of S-217622 to Fight COVID-19

Notice Regarding the Initiation of an Active Control Neutralizing Antibody Comparative Clinical Trial for COVID-19 Recombinant Protein-based Vaccine, S-268019 in Japan

Shionogi Announces Commitment to Fight COVID-19